Articles

Contrary to previous studies, new research finds SGLT-2i more effective for weight loss than GLP-1 RAs as add-on therapy to Metformin. 

Dasiglucagon is a glucagon analog stable in an aqueous formulation with FDA approval for severe hypoglycemia use. The target population is patients with diabetes who are six years of age and older, but how effective is it among other subgroups?

With the introduction of this new biosimilar insulin, patients with diabetes will have the opportunity to have easier and broader access to insulin therapy, and a more affordable option than those already on the market. 

Pediatric patients with T2D have accelerated onset of hypertension, dyslipidemia, kidney disease, nerve disease, and diabetic retinopathy.

Investigating whether a low-carb diet can lead to diabetes remission.

Physical activity is linked to mental health; how has the pandemic affected exercise options and mental well-being?

GD history is linked with coronary artery calcification (CAC) in women, an indicator of atherosclerotic CVD, and a predictor of CVD clinical events.

We know the positive effects of carbohydrate restriction on glycemia, but what is the impact on quality of life and cognition?

How has the pandemic affected the incidence of type 2 diabetes and other conditions such as Hyperosmolar Hyperglycemic Syndrome (HHS) within the younger population?

With the introduction of this glucagon-like peptide-1 receptor agonist (GLP-1 RA), efpeglenatide, could we see new cardiovascular and renal benefits for patients with type 2 diabetes?